Rotigotine transdermal system for the management of motor function and sleep disturbances in Parkinson's disease: Results from a 1-year, open-label extension of the RECOVER study

Basal Ganglia

Volumn 2, Issue 2, 2012, Pages 79-85

  Trenkwalder, C ^a   Kies, B ^b   Dioszeghy, P ^c   Hill, D ^d   Surmann, E ^e   Boroojerdi, B ^e   Whitesides, J ^e   Chaudhuri, K R ^f  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Department of Orthopaedics   (Hungary)

^d Central Carolina Neurology and Sleep   (United States)

^e UCB PHARMA   (Belgium)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Motor function; Open label; Parkinson's disease; RECOVER; Rotigotine; Sleep

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; ENTACAPONE; MODAFINIL; MONOAMINE OXIDASE B INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; ROTIGOTINE;

ABNORMAL DREAMING; ADULT; ANXIETY; APPLICATION SITE INFLAMMATION; APPLICATION SITE REACTION; APPLICATION SITE VESICLE; ARTICLE; CONFUSION; CONTROLLED STUDY; DELUSION; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; EATING DISORDER; ELECTROCARDIOGRAPHY; FALLING; FEMALE; FEMUR NECK FRACTURE; HALLUCINATION; HUMAN; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; PARASOMNIA; PARKINSON DISEASE; PARKINSON DISEASE SLEEP SCALE; PATIENT MONITORING; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; VITAL SIGN;

EID: 84862836106     PISSN: 22105336     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.baga.2012.05.009     Document Type: Article

References (28)

1. Happe S., Schrödl B., Faltl M., Happe S., Schrödl B., Faltl M., Müller C., Auff E., Zeitlhofer J. Sleep disorders and depression in patients with Parkinson's disease. Acta Neurol Scand 2001, 104:275-280.
2. Stocchi F., Barbato L., Nordera G., Berardelli A., Ruggieri S. Sleep disorders in Parkinson's disease. J Neurol 1998, 245(Suppl 1):S15-S18.
3. Tandberg E., Larsen J.P., Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 1998, 13:895-899.
4. Dusek P., Busková J., Růzicka E., Majerová V., Srp A., Jech R., Roth J., Sonka K. Effects of ropinirole prolonged-release on sleep disturbances and daytime sleepiness in Parkinson disease. Clin Neuropharmacol 2010, 33:186-190.
5. Högl B., Rothdach A., Wetter T.C., Trenkwalder C. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Neuropsychopharmacology 2003, 28:1866-1870.
6. Pahwa R., Stacy M.A., Factor S.A., Lyons K.E., Stocchi F., Hersh B.P., Elmer L.W., Truong D.D., Earl N.L. EASE-PD adjunct study investigators. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007, 68:1108-1115.
7. Rektorova I., Balaz M., Svatova J., Zarubova K., Honig I., Dostal V., Sedlackova S., Nestrasil I., Mastik J., Bares M., Veliskova J., Dusek L. Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study. Clin Neuropharmacol 2008, 31:261-266.
8. Romigi A., Stanzione P., Marciani M.G., Izzi F., Placidi F., Cervellino A., Giacomini P., Brusa L., Grossi K., Pierantozzi M. Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study. J Neural Transm 2006, 113:1909-1913.
9. Wolters E.C., Tesselaar H.J. International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease. J Neurol 1996, 243:235-240.
10. Trenkwalder C., Kies B., Rudzinska M., Fine J., Nikl J., Honczarenko K., Dioszeghy P., Hill D., Anderson T., Myllyla V., Kassubek J., Steiger M., Zucconi M., Tolosa E., Poewe W., Surmann E., Whitesides J., Boroojerdi B., Chaudhuri K.R., Recover Study Group Rotigotine effects on early morning motor function and sleep in Parkinson's Disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2011, 26:90-99.
11. LeWitt P.A., Boroojerdi B., Poewe W. On behalf of the SP516 and SP715 study groups. Long-term treatment of advanced Parkinson's disease with rotigotine. Movement disorder society - 14th international congress of Parkinson's disease and movement disorder. Mov Disord 2010, 25(Suppl. 2):S299-S300.
12. Poewe W.H., Rascol O., Quinn N., Tolosa E., Oertel W.H.L., Giladi N., Boroojerdi B. Long-term safety and efficacy of transdermal rotigotine in advanced Parkinson's disease. American academy of neurology 2009-61st annual meeting. Neurology 2009, 72(Suppl. 3):A321.
13. Watts R., Boroojerdi B., Jankovic J. Open-Label extension trial assessing the effects of long-term treatment with rotigotine in subjects with early-stage, idiopathic Parkinson's disease: results from up to 7years. Movement disorder society - 14th international congress of Parkinson's disease and movement disorder. Mov Disord 2010, 25(Suppl 2):S310-S311. on behalf of the SP702 study group.
14. Martínez-Martín P., Gil-Nagel A., Gracia L.M., Gómez J.B., Martinez-Sarriés J., Bermejo F. Unified Parkinson's disease rating scale characteristics and structure. Mov Disord 1994, 9:76-83. The Cooperative Multicentric Group.
15. Trenkwalder C., Kohnen R., Högl B., Metta V., Sixel-Döring F., Frauscher B., Hülsmann J., Martinez-Martin P., Chaudhuri K.R. Parkinson's disease sleep scale-validation of the revised version PDSS-2. Mov Disord 2011, 26:644-652.
16. Peto V., Jenkinson C., Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 1998, 245(Suppl. 1):S10-S14.
17. Visser M., Leentjens A.F., Marinus J., Stiggelbout A.M., van Hilten J.J. Reliability and validity of the Beck depression inventory in patients with Parkinson's disease. Mov Disord 2006, 21:668-672.
18. Martinez-Martin P., Rodriguez-Blazquez C., Abe K., Bhattacharyya K.B., Bloem B.R., Carod-Artal F.J., Prakash R., Esselink R.A., Falup-Pecurariu C., Gallardo M., Mir P., Naidu Y., Nicoletti A., Sethi K., Tsuboi Y., van Hilten J.J., Visser M., Zappia M., Chaudhuri K.R. International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease. Neurology 2009, 73:1584-1591.
19. Etminan M., Gill S., Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug Safety 2003, 26:439-444.
20. Olanow C.W., Rascol O., Hauser R., Feigin P.D., Jankovic J., Lang A., Langston W., Melamed E., Poewe W., Stocchi F., Tolosa E. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009, 361:1268-1278.
21. Hauser R.A., Rascol O., Korczyn A.D., Stoessl A.J., Watts R.L., Poewe W., De Deyn P.P., Lang A.E. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007, 22:2409-2417.
22. Maetzler W., Liepelt I., Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol 2009, 8:1158-1171.
23. Pahwa R., Stacy M.A., Factor S.A., Lyons K.E., Stocchi F., Hersh B.P., Elmer L.W., Truong D.D., Earl N.L. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007, 68:1108-1115. EASE-PD Adjunct Study Investigators.
24. Chaudhuri K.R., Martinez-Martin P., Rolfe K.A., Cooper J., Rockett C.B., Giorgi L., Ondo W.G. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease. Eur J Neurol 2012, 19:105-113.
25. Guttman M., Kish S.J., Furukawa Y. Current concepts in the diagnosis and management of Parkinson's disease. CMAJ 2003, 168:293-301.
26. Watts R.L., Jankovic J., Waters C., Rajput A., Boroojerdi B., Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007, 68:272-276.
27. Boroojerdi B., Wolff H.M., Braun M., Scheller D.K. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome. Drugs Today (Barc) 2010, 46:483-505.
28. Rascol O., Perez-Lloret S. Rotigotine transdermal delivery for the treatment of Parkinson's disease. Expert Opin Pharmacother 2009, 10:677-691.